BPC-157 (5mg) — Beligas

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids, derived from a protective protein naturally found in gastric juice. It is one of the most extensively researched peptides in preclinical science, with studies examining its effects on tissue repair, angiogenesis, tendon-to-bone healing, and gastrointestinal function.

What Is BPC-157?

BPC-157 is a stable gastric pentadecapeptide fragment studied for its regenerative properties in preclinical models. Unlike many research peptides, BPC-157 demonstrates oral and systemic stability, making it of significant interest across multiple research applications. It has been the subject of over 100 published studies examining its effects on a wide range of tissue and organ systems.

The peptide’s sequence — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — gives it structural resilience that is unusual among peptides of its size, contributing to its stability in biological environments.

BPC-157 Research Background

Musculoskeletal and connective tissue: Studies in rodent models have examined BPC-157’s influence on tendon, ligament, and muscle healing. Research published in the Journal of Physiology-Paris and Inflammatory Bowel Diseases documents accelerated healing of transected tendons in animal models, with researchers noting upregulation of growth hormone receptors at injury sites.

Gastrointestinal research: Given its origin as a gastric peptide, BPC-157 has been extensively studied in models of GI dysfunction. Research has examined its effects in models of inflammatory bowel disease, gastric ulceration, and intestinal fistulas. Studies suggest modulatory effects on nitric oxide pathways relevant to gut mucosal integrity.

Systemic effects: Animal studies have explored BPC-157’s interaction with dopaminergic and serotonergic systems, as well as its influence on blood pressure modulation via nitric oxide synthesis — areas of ongoing preclinical investigation.

All research referenced is conducted in preclinical animal models. BPC-157 is not approved for human therapeutic use in Australia and is not a TGA-registered therapeutic good.

Reconstitution Guidelines (Research Use)

BPC-157 is supplied as a lyophilised (freeze-dried) powder and requires reconstitution prior to use in research protocols.

Recommended reconstitution: Add bacteriostatic water (BAC water) to the vial slowly along the inner wall — avoid direct injection onto the powder. Gently swirl to dissolve. Do not shake.

Standard research concentrations: 1mg/ml to 2mg/ml depending on protocol requirements.

Peptide Reconstitution Calculator

Storage

• Store lyophilised powder at 2–8°C (refrigerated), protected from light
• Reconstituted solution: store at 2–8°C, use within 28 days
• For long-term storage of unreconstituted powder: -20°C recommended
• Avoid repeated freeze-thaw cycles

Research Stacking Notes

BPC-157 is frequently studied in combination with TB-500 (Thymosin Beta-4) in preclinical recovery models. The two peptides are believed to operate via complementary mechanisms — BPC-157 showing local tissue effects while TB-500 demonstrates systemic activity. The combination is one of the most documented peptide pairings in sports science and regenerative research literature.

Other research combinations include GHK-Cu for wound healing models and KPV for gastrointestinal inflammation research.

VITALITY CARTEL BPC-157 — Purity & Quality

Our BPC-157 is manufactured to 99%+ purity, verified by third-party HPLC analysis. Certificate of Analysis (CoA) available on request. Supplied as lyophilised powder in sealed vials with desiccant. Domestic AU dispatch. Available in 2mg, 5mg, and 15mg vials.

This product is not intended to diagnose, treat, cure, or prevent any disease.